Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.70 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8726594 | 0.96 | PTGS2 (0.65) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL11811163 | 0.88 | CXCL8 (0.53) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL8729408 | 0.87 | PTGS2 (0.72) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL8728811 | 0.84 | CXCL8 (0.57) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL7674683 | 0.84 | PTGS2 (0.76) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL11817601 | 0.83 | CXCL8 (0.52) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL11325188 | 0.82 | PTGS2 (1.00) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL3150 | 0.82 | PTGS2 (1.00) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL8726561 | 0.82 | PTGS2 (0.78) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL2237360 | 0.82 | PTGS2 (0.77) | PTGS2CXCL8AKR1B1PTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0783488-A4 | FIVE MEMBERED HETEROCYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO (JP) | 1998-01-07 | — | — | EP | claimed |
| EP-0783488-A1 | FIVE MEMBERED HETEROCYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-07-16 | — | — | EP | claimed |
| WO-1996010013-A1 | FIVE MEMBERED HETEROCYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-04 | — | — | WO | claimed |
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | PTGS2 887/4885CXCL8 3828/4885AKR1B1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.